Skip to main navigation Skip to search Skip to main content

HM2026-25 Relative Bioavailability and Bioequivalence Study of Ziftomenib Drug Products in Participants with Relapsed/Refractory AML with NPM1 Mutation, or with Relapsed/Refractory AML or MDS with Mutations Associated with MEIS1 Overexpression

Project: Research project

Project Details

StatusActive
Effective start/end date7/17/26 → 9/9/36

Funding

  • KURA ONCOLOGY, INC